Compare HFWA & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFWA | IVA |
|---|---|---|
| Founded | 1927 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 748.4M | 769.0M |
| IPO Year | N/A | 2020 |
| Metric | HFWA | IVA |
|---|---|---|
| Price | $25.37 | $4.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $29.33 | $17.14 |
| AVG Volume (30 Days) | 187.7K | ★ 237.5K |
| Earning Date | 01-22-2026 | 09-29-2025 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | ★ 53.03 | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $232,877,000.00 | $19,929,536.00 |
| Revenue This Year | $21.61 | N/A |
| Revenue Next Year | $29.10 | N/A |
| P/E Ratio | $15.29 | ★ N/A |
| Revenue Growth | ★ 14.16 | N/A |
| 52 Week Low | $19.84 | $2.11 |
| 52 Week High | $26.58 | $7.98 |
| Indicator | HFWA | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 72.07 | 53.67 |
| Support Level | $24.01 | $4.05 |
| Resistance Level | $25.53 | $4.61 |
| Average True Range (ATR) | 0.56 | 0.20 |
| MACD | 0.18 | 0.07 |
| Stochastic Oscillator | 91.46 | 84.62 |
Heritage Financial Corp is a bank holding company. The company through its subsidiary provides commercial lending and deposit relationships with small businesses and their owners in its market areas and attracts deposits from the general public. It accepts various deposit products, such as noninterest demand accounts, money market accounts, savings accounts, and certificates of deposit. Besides, the Bank also makes real estate construction loans, land development loans, and consumer loans, and originates first mortgage loans on residential properties mainly located in its market area. Geographically, all the business activity functions through the region of the United States.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.